These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15880941)

  • 1. Substance P upregulates osteoclastogenesis by activating nuclear factor kappa B in osteoclast precursors.
    Sohn SJ
    Acta Otolaryngol; 2005 Feb; 125(2):130-3. PubMed ID: 15880941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
    Kanazawa K; Kudo A
    J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors.
    Sugatani T; Alvarez UM; Hruska KA
    J Cell Biochem; 2003 Sep; 90(1):59-67. PubMed ID: 12938156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis.
    Merle B; Itzstein C; Delmas PD; Chenu C
    J Cell Biochem; 2003 Oct; 90(2):424-36. PubMed ID: 14505357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha.
    Hayashi S; Yamada T; Tsuneto M; Yamane T; Takahashi M; Shultz LD; Yamazaki H
    J Immunol; 2003 Nov; 171(10):5130-9. PubMed ID: 14607912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor.
    Kaneda T; Nojima T; Nakagawa M; Ogasawara A; Kaneko H; Sato T; Mano H; Kumegawa M; Hakeda Y
    J Immunol; 2000 Oct; 165(8):4254-63. PubMed ID: 11035059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
    Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
    J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substance P stimulates bone marrow stromal cell osteogenic activity, osteoclast differentiation, and resorption activity in vitro.
    Wang L; Zhao R; Shi X; Wei T; Halloran BP; Clark DJ; Jacobs CR; Kingery WS
    Bone; 2009 Aug; 45(2):309-20. PubMed ID: 19379851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-kappaB activity.
    Ren W; Li XH; Chen BD; Wooley PH
    J Orthop Res; 2004 Jan; 22(1):21-9. PubMed ID: 14656655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor activator of NF-kappaB ligand-stimulated osteoclastogenesis in mouse marrow culture is suppressed by zinc in vitro.
    Yamaguchi M; Uchiyama S
    Int J Mol Med; 2004 Jul; 14(1):81-5. PubMed ID: 15202020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis.
    Bharti AC; Takada Y; Aggarwal BB
    J Immunol; 2004 May; 172(10):5940-7. PubMed ID: 15128775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-assembled RANK induces osteoclastogenesis ligand-independently.
    Kanazawa K; Kudo A
    J Bone Miner Res; 2005 Nov; 20(11):2053-60. PubMed ID: 16234979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.
    Tsujisawa T; Inoue H; Nishihara T
    J Bone Miner Res; 2005 Jan; 20(1):15-22. PubMed ID: 15619665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis.
    Park H; Jung YK; Park OJ; Lee YJ; Choi JY; Choi Y
    J Immunol; 2005 Dec; 175(11):7193-201. PubMed ID: 16301623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipopolysaccharide-induced osteoclastogenesis in Src homology 2-domain phosphatase-1-deficient viable motheaten mice.
    Hayashi S; Tsuneto M; Yamada T; Nose M; Yoshino M; Shultz LD; Yamazaki H
    Endocrinology; 2004 Jun; 145(6):2721-9. PubMed ID: 14988381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.